In last trading session, Connect Biopharma Holdings Ltd ADR (NASDAQ:CNTB) saw 0.51 million shares changing hands with its beta currently measuring -0.31. Company’s recent per share price level of $2.05 trading at $0.06 or 3.02% at ring of the bell on the day assigns it a market valuation of $112.89M. That closing price of CNTB’s stock is at a discount of -5.85% from its 52-week high price of $2.17 and is indicating a premium of 74.15% from its 52-week low price of $0.53. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 41270.0 shares which gives us an average trading volume of 57.33K if we extend that period to 3-months.
For Connect Biopharma Holdings Ltd ADR (CNTB), analysts’ consensus is at an average recommendation of a Buy while assigning it a mean rating of 1.00. Splitting up the data highlights that, out of 1 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 0 suggested the stock as a Hold whereas 1 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of $0 in the current quarter.
Connect Biopharma Holdings Ltd ADR (NASDAQ:CNTB) trade information
Upright in the green during last session for gaining 3.02%, in the last five days CNTB remained trading in the green while hitting it’s week-highest on Friday, 11/17/23 when the stock touched $2.05 price level, adding 27.82% to its value on the day. Connect Biopharma Holdings Ltd ADR’s shares saw a change of 136.23% in year-to-date performance and have moved 23.49% in past 5-day. Connect Biopharma Holdings Ltd ADR (NASDAQ:CNTB) showed a performance of 73.73% in past 30-days. Number of shares sold short was 29370.0 shares which calculate 0.32 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of $50.96 to the stock, which implies a rise of 95.98% to its current value. Analysts have been projecting $50.96 as a low price target for the stock while placing it at a high target of $50.96. It follows that stock’s current price would drop -2385.85% in reaching the projected high whereas dropping to the targeted low would mean a loss of -2385.85% for stock’s current value.
Connect Biopharma Holdings Ltd ADR (CNTB) estimates and forecasts
Statistics highlight that Connect Biopharma Holdings Ltd ADR is scoring comparatively higher than the scores of other players of the relevant industry. The company added 86.36% of value to its shares in past 6 months, showing an annual growth rate of 47.14% while that of industry is 14.80. Apart from that, the company came raising its revenue forecast for fiscal year 2023.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of -80.56% during past 5 years.
Connect Biopharma Holdings Ltd ADR is more likely to be releasing its next quarterly report on September 12 and investors are confident in the company announcing better current-quarter dividends despite the fact that it has been facing issues arising out of mounting debt.
Connect Biopharma Holdings Ltd ADR (NASDAQ:CNTB)’s Major holders
Insiders are in possession of 39.86% of company’s total shares while institution are holding 39.87 percent of that, with stock having share float percentage of 66.29%. Investors also watch the number of corporate investors in a company very closely, which is 39.87% institutions for Connect Biopharma Holdings Ltd ADR that are currently holding shares of the company. RA Capital Management, L.P. is the top institutional holder at CNTB for having 6.99 million shares of worth $7.9 million. And as of Jun 29, 2023, it was holding 12.69% of the company’s outstanding shares.
The second largest institutional holder is Blackrock Inc., which was holding about 1.13 million shares on Jun 29, 2023. The number of shares represents firm’s hold over 2.04% of outstanding shares, having a total worth of $1.27 million.
On the other hand, BlackRock Health Sciences Term Trust and Fidelity NASDAQ Composite Index Fund are the top two Mutual Funds which own company’s shares. As of Jun 29, 2023, the former fund manager was holding 1.13 million shares of worth $1.27 million or 2.04% of the total outstanding shares. The later fund manager was in possession of 19032.0 shares on May 30, 2023, making its stake of worth around $20626.0 in the company or a holder of 0.03% of company’s stock.